Drugs / TEV-56278
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06480552 | Jul 2024 → May 2029 expected | cancer | Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory Fosun Pharma and Teva's Co-Developed Innovative Anti-Tumor Immunotherapy Drug FXB0871 Approved for Phase 1 Clinical Trial in China fosunpharma.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma and Teva's Co-Developed Innovative Anti-Tumor Immunotherapy Drug FXB0871 Approved for Phase 1 Clinical Trial in China fosunpharma.com ↗ |
| 2025-06-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology tevapharm.com ↗ |
| 2025-06-16 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology fosunpharma.com ↗ |
| 2025-06-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology tevapharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEV-56278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06480552 ↗ |
| Route | Intravenous | “Administered intravenously” NCT06480552 ↗ |